Management | NeuroBo Pharmaceuticals, Inc.

Prior to his appointment as Chief Executive Officer and President of the Company, Mr. Kim was the General Counsel and a Senior Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs and Mr. Kim has been serving as a member of the Company’s Board since July 2021. Mr. Kim previously served as Executive Director of Dong-A ST from 2018 through 2020 and as Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. During his time at Dong-A ST and Dong-A Socio Holdings, he negotiated many significant transactions, including licensing and investment transactions. Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private, Swiss-based provider of scientific research and development services. Mr. Kim previously served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. He received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.

Marshall has more than 35 years of experience in financial roles of increasing responsibility including over 20 years of experience in life sciences and related sectors. Prior to joining NeuroBo, Marshall held CFO roles with Nevakar Inc., Braeburn Pharmaceuticals Inc., Aerocrine AB and Furiex Pharmaceuticals Inc. During his career, Marshall has worked for a number of companies including: Eli Lilly, Dow Chemical, Monsanto, Milliken and others. Marshall brings a wealth of experience in private and public company management and stewardship and has extensive experience working with investors and analysts in the life science sector.

Throughout his career, Marshall has contributed to the success of companies by acting as a key resource and advisor to management, working closely with R&D and operations, and ensuring that finance functions are informed by a deep understanding of programmatic operations.

Marshall holds a BS degree from the University of Maryland College Park and an MBA from Indiana University in Bloomington.

Dr. Mi-Kyung Kim has served as a Vice President, leading the overall new drug discovery research for metabolic and immune-mediated diseases at Dong-A ST. She has more than 25 years of experience in the pharmaceutical industry. She has a high level of understanding of new drug development, experiencing both domestic and global clinical development, as well as overall new drug development from initial drug discovery to new drug approval while leading the project. She has specialized research experience focusing on chronic endocrine/cardiometabolic disease era such as diabetes, obesity, NASH, chronic kidney disease and osteoporosis. During her career at Dong-A, she has led numerous projects, including a novel dipeptidyl peptidase inhibitor (evogliptin, Suganon®), which became the world ninth approved product for the treatment of type 2 diabetes. DA-1241 and DA-1726 are new drug candidates for metabolic diseases, and she has been establishing drug evaluation and development strategies while establishing the concept of drugs from the initial target selection stage of these two projects to the present. Academically, after she graduated from the College of Pharmacy at Ewha Womans University in Korea, she studied cancer metastasis and beta cell biology/proteomics in the same graduate school.

Dr. Chris Fang is a physician-scientist with over 20 years of experience in clinical development, R&D, and medical affairs. Before joining NeuroBo, he served as Chief Medical Officer and President of R&D at Sidekick Health, collaborating with partners such as Eli Lilly, AstraZeneca, and Pfizer. Previously, he was Vice President of Global Medical Affairs at Eli Lilly, where he established an integrated clinical evidence strategy for key products in the cardiometabolic space. Before that, Dr. Fang was the Global Head of R&D Solutions at IQVIA and the Chief Executive Officer and co-founder of Acer Health. Earlier in his career, he served as Worldwide Vice President of Strategic Medical Sciences at Johnson & Johnson, and also held various clinical development positions at Medtronic, Mitsubishi Pharma, and Idenix Pharmaceuticals.

Dr. Fang earned a Bachelor of Arts from the University of California, Los Angeles, a Master of Health Science from Johns Hopkins School of Public Health, an MD from Weill Cornell Medical College, and an MBA from the Wharton School at the University of Pennsylvania.

Robert Homolka is an experienced clinical development operations executive with a strong track record of improving efficiency and compliance in clinical development programs. He has successfully led cross-functional teams in designing and executing clinical trials, managing budgets, and timelines. Notable for his cost-saving initiatives and effective vendor negotiations, he has integrated FDA and ICH regulatory standards into company practices. With extensive experience managing Phase I to IV clinical research projects, He has launched and optimized clinical operations for multiple biopharmaceutical companies. He has managed clinical trial activities across various therapeutic areas and played key roles in trials for compounds such as ZD4522, AZD-7371, NXY-059, and others. He has held senior roles at Cyclone Consulting, Adiso Therapeutics, Shire/Takeda Pharmaceuticals, and AstraZeneca Pharmaceuticals, overseeing clinical operations and ensuring regulatory compliance. He has a Master of Science in Integrated Pharmacology, a Master of Business Administration, and a Bachelor of Science in Microbiology. He has presented at industry conferences and contributed to publications in the field.